ReviewInternational journal of molecular sciences2025
Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in chrysin research for cardiovascular disorders: mechanistic insights and therapeutic prospects.Molecular biology reports · 2026Review
- Special Issue: Recent Research on Hypertension and Related Complications.International journal of molecular sciences · 2026Article
- Liensinine Ameliorating Oxidative Damage to Vascular Endothelium In Vitro via Upregulating eNOS and Nrf2/HO-1 Signaling.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pulmonary hypertension (PH) is a progressive and life-threatening disorder characterized by elevated pulmonary arterial pressure, leading to right ventricular remodeling and significant mortality. Pulmonary arterial remodeling, a critical pathological feature of PH, refers to structural alterations in the pulmonary vasculature driven by various pathogenic factors. Targeting this remodeling process has emerged as a promising strategy for treating and potentially curing the disease. In recent years, growing interest has been directed toward exploring natural products as anti-PH agents. Among them, flavonoids have demonstrated potent efficacy in the cardiopulmonary system. As a prominent class of natural small-molecule compounds, flavonoids exhibit broad biological activities, such as antioxidant, anti-inflammatory, and anti-proliferative properties. They have shown the ability to inhibit remodeling and restore vascular function across various vessel types, including pulmonary arteries. This review summarizes the effects of flavonoids on PH, with emphasis on their inhibition of pulmonary arterial remodeling. We also discuss the therapeutic potential of flavonoids in PH and discuss their underlying mechanisms of action. These insights may guide the development of next-generation PH therapeutics, either through the utilization of flavonoid-based structures or the preparation of compound formulations containing flavonoids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.